COgnitioN With VERiciGuat Evaluation in Heart Failure

What this study is about

CONVERGE-HF is a 4-center pilot phase IIb randomized control trial in ambulatory patients with chronic heart failure (≥ 6 months) and mild-to-moderate cognitive impairment.

Who can join (things the study team will check)

✅ You may be able to join if…

• Adult patients
• Established chronic heart failure (≥ 6 months)
• Mild-to-moderate cognitive impairment (as per the diagnosis of cognitive impairment or a Montreal Cognitive Assessment (MoCA) score 10-25).

🚫 You may not be able to join if…

• Patients who have contraindications for sGC stimulator and vericiguat therapy (i.e. use of long-acting nitrates, other soluble guanylate cyclase stimulators (e.g., riociguat), or phosphodiesterase type 5 (PDE-5), pregnancy or breast-feeding)
• Unable to undergo CMR imaging or brain MRI.
• CMR exclusions: incompatible implantable cardiac device (ICD or CRT), uncontrolled atrial fibrillation or recurrent ventricular arrhythmias).
• General medical conditions: uncontrolled thyroid disorders, hepatic failure, or myocardial revascularization procedures [coronary angioplasty and/or surgical revascularization in the previous 3 months], cancer/malignancy, or with severe dementia).
• Patients with allergies to the study products.
• Patients currently hospitalized.

Where this trial is running

• University of Calgary, Calgary, Alberta, Canada
• University of Alberta, Edmonton, Alberta, Canada
• University of Ottawa, Ottawa, Ontario, Canada
• McGill University Health Center, Montreal, Quebec, Canada

Who to contact

Justin Ezekowitz, MBBCh, MSc · 780-492-0712 · jae2@ualberta.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06601465.